Skip to Menu Skip to Search Contact Us Skip to Content

SGS, a leading bio/pharmaceutical analytical and bioanalytical contract solutions provider, today announced that it has introduced comprehensive drug compatibility study testing at its Shanghai laboratory in China.

This new service, for the analysis of potential extractable and leachable contamination within pharmaceutical products, harmonizes services offered in this field across SGS’s global network of laboratories.
 
China’s Center for Drug Evaluation (CDE) made drug compatibility studies mandatory for all New Drug Applications (NDAs) and Abbreviated New Drug Applications (ANDAs) in 2014. SGS’s investment in these services comes after a multi-stage expansion of its laboratory in Shanghai, which was completed in 2015. It includes the installation and validation of new quadrupole time-of-flight (Q-TOF), liquid chromatography-diode array-mass spectrometry (LC-DAD-MS) and gas chromatography–mass spectrometry (GC-MS) instruments.
 
“We have seen an increased demand for these services since the regulations have been tightened, and we have been working with regulatory bodies and industry associations to help define and establish definitive testing guidelines in this area going forward,” commented Andy Yi, General Manager, SGS Life Science, Shanghai. “With this investment, SGS has been able to build on its strong reputation to attract new customers as well as increase business, with pharmaceutical R&D teams looking to engage with experts earlier in the process to ensure compliance.”
 
SGS has been providing extractable and leachable testing services from its Shanghai facility to local clients, and international clients with a presence in China, since the facility opened in 2006. Expansion of the facility commenced in 2014 and initially included increased capabilities in cGMP chemistry and biotechnology testing laboratories. The microbiology laboratory was expanded subsequently, increasing the total floor space to 3,200 square meters.
 
With 20 laboratories offering contract analytical and bioanalytical services, SGS leverages its wholly-owned global network, present in North America, Europe, and Asia, to deliver harmonized solutions to large pharmaceutical and biotechnology firms. In addition to testing services for the bio/pharmaceutical market, SGS also provides Phase I-IV clinical trial management, and services encompassing data management and statistics, PK/PD modeling and simulation, pharmacovigilance and regulatory consultancy.
 
For further information, please contact:
 
Ferdinand Dabu
Life Sciences – Global Marketing Director
Agriculture, Food and Life
SGS, 75 Passaic Avenue, Fairfield, NJ 07004, USA
t: +1-973-287-1219
www.sgs.com/lifescience
 
Richard Kerns

President
NEPR
t: +44 (0)161 728 5880

About SGS

SGS is the world’s leading inspection, verification, testing and certification company. SGS is recognized as the global benchmark for quality and integrity. With more than 85,000 employees, SGS operates a network of over 1,800 offices and laboratories around the world.